Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Aerosol Challenge
100%
Vaccine Evaluation
100%
Tuberculosis
100%
Challenge Model
100%
Rhesus Macaque
100%
Nonhuman Primate
100%
Mycobacterium Tuberculosis (M. tb)
66%
Disease Burden
66%
Challenge Study
66%
Tuberculosis Vaccine
66%
Group Size
66%
Vaccination
33%
Enzyme-linked Immunosorbent Assay (ELISA)
33%
Interferon-γ
33%
Interferon Response
33%
Response to Vaccination
33%
Efficacy Study
33%
Vaccine Effectiveness
33%
Vaccination Strategy
33%
Interferon-α (IFN-α)
33%
Human Trials
33%
Unvaccinated
33%
Long-term Survival
33%
Vaccination Protocols
33%
Nonclinical
33%
Magnetic Resonance Imaging
33%
Enzyme-linked Immunospot Assay
33%
Lung Lesions
33%
Purified Protein Derivative
33%
Subtle Differences
33%
Animal Survival
33%
Aerosol Administration
33%
Stereology
33%
Lesion Burden
33%
Medicine and Dentistry
Disease Burden
100%
BCG Vaccine
100%
Clinical Trial
50%
Efficacy Study
50%
Enzyme Linked Immunosorbent Assay
50%
Mycobacterium Tuberculosis
50%
Evaluation Study
50%
Gamma Interferon
50%
Tuberculin
50%
Interferon
50%
Long Term Survival
50%
Magnetic Resonance Imaging
50%
Lung Lesion
50%
Enzyme Linked Immunospot Assay
50%
Stereology
50%
Vaccine Efficacy
50%
Pharmacology, Toxicology and Pharmaceutical Science
Rhesus Monkey
100%
BCG Vaccine
66%
Diseases
66%
Clinical Trial
33%
Enzyme-Linked Immunosorbent Assay
33%
Mycobacterium Tuberculosis
33%
Gamma Interferon
33%
Efficacy Study
33%
Tuberculin
33%
Interferon
33%
Long Term Survival
33%
Lung Lesion
33%
Enzyme-Linked Immunospot Assay
33%
Vaccine Efficacy
33%
Immunology and Microbiology
Rhesus Monkey
100%
Disease Burden
66%
BCG Vaccine
66%
Vaccine Efficacy
33%
interferon
33%
Enzyme-Linked Immunosorbent Assay
33%
Mycobacterium Tuberculosis
33%
Interferon Gamma
33%
Tuberculin
33%
Magnetic Resonance Imaging
33%
Long Term Survival
33%
Enzyme-Linked Immunospot Assay
33%